CORT Stock Overview
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States.
Corcept Therapeutics Incorporated Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$28.41|
|52 Week High||US$29.93|
|52 Week Low||US$15.83|
|1 Month Change||6.33%|
|3 Month Change||50.00%|
|1 Year Change||37.38%|
|3 Year Change||118.71%|
|5 Year Change||95.66%|
|Change since IPO||132.30%|
Recent News & Updates
Corcept cut to Hold at Truist on balanced risk-reward setup
Citing a more balanced risk-reward profile following the recent outperformance of company shares, Truist downgraded commercial-stage pharma Corcept Therapeutics (NASDAQ:CORT) to Hold from Buy on Monday. The analyst Gregory Fraser highlights Corcept (CORT) shares registered over 45% gain this year compared to the ~13% decline in the S&P 500 and ~28% selloff in the S&P SPDR Biotech ETF (XBI). The analyst attributes the upsurge mainly to the growth potential of the company’s Cushing’s franchise and the longer-term prospects of its pipeline. Given the modest upside indicated in its $30 per share target, Fraser downgrades the stock as he sees a more balanced risk-reward set up for the stock. Truist’s view on Corcept (CORT) contrasts with that of Jefferies, which launched its coverage on the stock last week with a Buy recommendation citing the profitability of the company's Cushing Syndrome drug Korlym. Wall Street has remained bullish on Corcept (CORT) stock, with an average rating of Buy from analysts, while Seeking Alpha's quant system, which consistently beats the market, rated CORT as a Hold.
|CORT||US Pharmaceuticals||US Market|
Return vs Industry: CORT exceeded the US Pharmaceuticals industry which returned 0.7% over the past year.
Return vs Market: CORT exceeded the US Market which returned -11.7% over the past year.
|CORT Average Weekly Movement||6.1%|
|Pharmaceuticals Industry Average Movement||11.7%|
|Market Average Movement||7.7%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: CORT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: CORT's weekly volatility (6%) has been stable over the past year.
About the Company
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing’s syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess.
Corcept Therapeutics Incorporated Fundamentals Summary
|CORT fundamental statistics|
Is CORT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CORT income statement (TTM)|
|Cost of Revenue||US$5.20m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||1.05|
|Net Profit Margin||28.75%|
How did CORT perform over the long term?See historical performance and comparison